Clinical Trial Update: Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab and tremelimumab in hormone receptor-positive, hypermutated metastatic breast cancer identified by whole exome sequencing ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Yonsei University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED